<DOC>
	<DOC>NCT00605163</DOC>
	<brief_summary>The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP 1347 in Patients With Early Parkinson's Disease). The study will assess the clinical and imaging outcomes relevant to the natural history of Parkinson's disease (PD), as well as determine early biomarkers of the disease.</brief_summary>
	<brief_title>A Longitudinal Observational Follow-up of the PRECEPT Study Cohort</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Participation in the PRECEPT study Willing and able to give informed consent Patients will be excluded from participating in the the study if either of the criteria stated above is not met</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Parkinson disease, observational, longitudinal</keyword>
</DOC>